Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31st, 2025 ("Financial Statements"). Theralase® will be hosting a conference call on May 12 th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31st, 2025.